Cipla-Glenmark recalled medicines from the American market: Defect in Cipla’s packing, Glenmark’s medicine is not as per the standard.

Drug manufacturing companies Cipla and Glenmark are recalling their medicines from the American market due to manufacturing issues. Cipla’s New Jersey-based subsidiary has recalled 59,244 packs of Ipratropium Bromide and Albuterol Sulfate Inhalation Solution, reported the US Food and Drug Administration (USFDA).

Cipla USA has recalled these lots of medicines due to “short fill”. According to USFDA, the quantity of medicine in these medicine pouches was less than the prescribed limit. Apart from this, there were also drops of liquid in the pouches.

These medicines were manufactured in India

These medicines were manufactured in a SEZ plant in Indore city of India. These medications are used to help control the symptoms of lung diseases such as asthma, chronic bronchitis, and emphysema.

Glenmark also recalled high blood pressure medicine

Glenmark Pharma has recalled 3,264 bottles of capsules of diltiazem hydrochloride, a drug used to control high blood pressure. Glenmark’s US-based branch Glenmark Pharmaceuticals Inc. is withdrawing the drug due to some shortcomings in its manufacturing.

The company started the recall from April 17, 2024. According to the USFDA, the recalled drugs were not expected to cause any major harm.

Cipla is India’s second largest pharmaceutical company.

Cipla is India’s second largest pharmaceutical manufacturing company. It has manufacturing units in 47 locations across the world. It supplies its products in 86 countries of the world. The market cap of the company is Rs 1.15 lakh crore.